S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
LON:ONC

Oncimmune Share Forecast, Price & News

GBX 204.61
-2.39 (-1.15 %)
(As of 03/5/2021 09:49 AM ET)
Add
Compare
Today's Range
204
Now: GBX 204.61
210
50-Day Range
164.50
MA: GBX 186.20
221.50
52-Week Range
38.50
Now: GBX 204.61
222
Volume164,845 shs
Average Volume79,615 shs
Market Capitalization£130.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Headlines

Oncimmune loss narrows on revenue boost
February 15, 2021 |  marketwatch.com
Oncimmune Holdings PLC
November 14, 2020 |  barrons.com
Oncimmune Holdings PLC (OCMMF)
August 17, 2020 |  nasdaq.com
Oncimmune Holdings share price hits a new 52 week high
June 16, 2020 |  uk.finance.yahoo.com
BRIEF-Oncimmune Announces Commercial Launch In U.S.
March 4, 2020 |  www.reuters.com
Consortium of Liver Cancer Industry Leaders
January 23, 2020 |  www.lse.co.uk
See More Headlines

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-115-8231869
Employees72
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£2.03 million
Cash FlowGBX 5.20 per share
Book ValueGBX (3.80) per share

Profitability

Miscellaneous

Market Cap£130.36 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.42 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 204.61
-2.39 (-1.15 %)
(As of 03/5/2021 09:49 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oncimmune (LON:ONC) Frequently Asked Questions

What stocks does MarketBeat like better than Oncimmune?

Wall Street analysts have given Oncimmune a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncimmune wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Oncimmune's earnings last quarter?

Oncimmune Holdings plc (LON:ONC) issued its quarterly earnings data on Tuesday, February, 13th. The company reported ($5.70) earnings per share (EPS) for the quarter. The business had revenue of $0.08 million for the quarter.
View Oncimmune's earnings history
.

How has Oncimmune's stock price been impacted by COVID-19 (Coronavirus)?

Oncimmune's stock was trading at GBX 70.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ONC stock has increased by 190.2% and is now trading at GBX 204.61.
View which stocks have been most impacted by COVID-19
.

Who are Oncimmune's key executives?

Oncimmune's management team includes the following people:
  • Dr. Adam Mark Hill Ph.D., CEO & Director (Age 41, Pay $385k)
  • Mr. Matthew Hall, Chief Financial Officer
  • Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Chief Scientific Officer
  • Ms. Cléa Rosenfeld, Head of Investor Relations
  • Mr. Ron Kirschner, Gen. Counsel & Company Sec.
  • Dr. James R. Jett M.D., Chief Medical Officer of US
  • Mr. Maarten Brusse, Chief Commercial Officer of Asia
  • Mr. Shane Smith, Sr. VP of Market Access & Reimbursement Oncimmune (Usa)
  • Mr. Matthew Luttrell, Chief Commercial Officer
  • Mr. Andrew Millet BA, FCA, MBA, Exec. (Age 54)

Who are some of Oncimmune's key competitors?

What other stocks do shareholders of Oncimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), (APHA), (AQB), Axsome Therapeutics (AXSM), (BGSF), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST).

What is Oncimmune's stock symbol?

Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC."

How do I buy shares of Oncimmune?

Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oncimmune's stock price today?

One share of ONC stock can currently be purchased for approximately GBX 204.61.

How much money does Oncimmune make?

Oncimmune has a market capitalization of £130.36 million and generates £2.03 million in revenue each year.

How many employees does Oncimmune have?

Oncimmune employs 72 workers across the globe.

What is Oncimmune's official website?

The official website for Oncimmune is oncimmune.com.

Where are Oncimmune's headquarters?

Oncimmune is headquartered at Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom.

How can I contact Oncimmune?

Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869.


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.